ReviewThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi2025
[Drug Therapy for Gastroesophageal Reflux Disease].
Review in The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastroesophageal reflux disease (GERD) is a common condition primarily treated with acid-suppressive therapies such as proton pump inhibitors (PPIs) or potassium competitive acid blockers (P-CABs). However, many patients experience a suboptimal response to PPIs or symptom recurrence upon discontinuation, leading to an increased economic burden and reduced quality of life. For patients unresponsive to PPIs, objective tests such as reflux monitoring are essential to differentiate GERD from other conditions or to understand the underlying mechanisms causing the reflux. Strategies like optimizing adherence, dose escalation, switching to other PPIs, or transitioning to P-CABs can improve treatment outcomes. Use of neuromodulators may benefit patients with functional heartburn or reflux hypersensitivity. For those requiring maintenance therapy, explaining the advantages and disadvantages of continuous versus on-demand treatment and providing clear guidance can help achieve effective symptom control with the minimal necessary dosage of the medication. Sequential maintenance therapy, which begins with daily medication and transitions to on-demand therapy, is effective in improving patient satisfaction while minimizing drug exposure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.